Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $53.14 Average PT from Brokerages
Shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) have received a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued a report on […]
Shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) have received a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued a report on […]
